NasdaqGM:RYTMBiotechs
Does EU IMCIVREE Expansion for Hypothalamic Obesity Change The Bull Case For Rhythm (RYTM)?
Rhythm Pharmaceuticals recently announced that the European Commission expanded marketing authorization for IMCIVREE (setmelanotide) to treat obesity and control hunger in adults and children aged 4 and above with acquired hypothalamic obesity due to hypothalamic injury or impairment, based on Phase 3 TRANSCEND trial data showing a placebo-adjusted reduction in body mass index.
This twin US and EU approval for acquired hypothalamic obesity meaningfully broadens IMCIVREE’s addressable patient...